{"organizations": [], "uuid": "dbbb62ec0dae3f21770c96026ad9794d12001cdf", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180220.html", "section_title": "Archive News &amp; Video for Tuesday, 20 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-voyager-therapeutics-and-abbvie-an/brief-voyager-therapeutics-and-abbvie-announce-global-strategic-collaboration-idUSFWN1QA0FN", "country": "US", "domain_rank": 408, "title": "BRIEF-Voyager Therapeutics And Abbvie Announce Global Strategic Collaboration", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.128, "site_type": "news", "published": "2018-02-20T20:18:00.000+02:00", "replies_count": 0, "uuid": "dbbb62ec0dae3f21770c96026ad9794d12001cdf"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-voyager-therapeutics-and-abbvie-an/brief-voyager-therapeutics-and-abbvie-announce-global-strategic-collaboration-idUSFWN1QA0FN", "ord_in_thread": 0, "title": "BRIEF-Voyager Therapeutics And Abbvie Announce Global Strategic Collaboration", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "abbvie inc", "sentiment": "negative"}, {"name": "alzheimer", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 20 (Reuters) - Abbvie Inc:\n* VOYAGER THERAPEUTICS AND ABBVIE ANNOUNCE GLOBAL STRATEGIC COLLABORATION TO DEVELOP POTENTIAL NEW TREATMENTS FOR ALZHEIMERâ€™S DISEASE AND OTHER TAU-RELATED NEURODEGENERATIVE DISEASES\n* VOYAGER THERAPEUTICS INC - VOYAGER TO RECEIVE $69 MILLION UPFRONT PAYMENT AND POTENTIALLY UP TO $155 MILLION IN PRECLINICAL AND PHASE 1 OPTION PAYMENTS\n* VOYAGER THERAPEUTICS - IS ALSO ELIGIBLE TO GET UP TO $895 MILLION IN DEVELOPMENT AND REGULATORY MILESTONES FOR EACH VECTORIZED TAU ANTIBODY COMPOUND Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-20T20:18:00.000+02:00", "crawled": "2018-02-21T21:12:56.000+02:00", "highlightTitle": ""}